Tags

Type your tag names separated by a space and hit enter

Serum levels of cardiac troponin I and other marker proteins in patients with chronic renal failure.
Clin Exp Nephrol. 2004 Mar; 8(1):43-7.CE

Abstract

BACKGROUND

Serum levels ob biochemical markers for acute myocardial infarction (AMI) can be increased in patients with chronic renal failure (CRF) or skeletal muscle injury, creating diagnostic confusion. We evaluated the clinical utility of cardiac troponin I (cTnI) as a marker of AMI, particularly in patients with CRF.

METHODS

Subjects consisted of 59 healthy volunteers and 102 patients: 61 with CRF undergoing hemodialysis (CRF-HD), 10 with CRF under conservative therapy (CRF-CT), 21 with renal disease (RD), and 10 with muscle disease (MD). Patients with RD, CRF, and MD were evaluated to verify the absence of myocardial injury. We developed an immunoradiometric assay to measure serum cTnI using monoclonal antibodies. The lower limit of detection was 0.33 micro g/l. Serum cTnI, creatine kinase (CK), CK-MB, cardiac troponin T (first-, second-, and third-generation assay: cTnT-I, cTnT-II, and cTnT-III), and cardiac myosin light chain 1 (cMLC1) were measured.

RESULTS

cTnI was not detected in healthy volunteers or patients with CRF, RD, or MD. In patients with CRF-HD, elevated levels occurred in 4.9% (3/61) for CK, 0% (0/61) for CK-MB, 39.5% (15/38) for cTnT-I, 7.3% (3/41) for cTnT-II, 13.0% (3/23) for cTnT-III, and 77.0% (47/61) for cMLC1; and in patients with MD the levels were increased in 70% (7/10) for CK, 50% (5/10) for CK-MB, 44.4% (4/9) for cTnT-I, 20% (2/10) for cTnT-II, and 50% (5/10) for cMLC1.

CONCLUSIONS

cTnI is a highly specific marker for AMI and is particularly useful for detecting AMI in patients with CRF or MD. Serum levels of biochemical markers for acute myocardial infarction (AMI) can be increased in patients with chronic renal failure (CRF) or skeletal muscle injury, creating diagnostic confusion. We evaluated the clinical utility of cardiac troponin I (cTnI) as a marker of AMI, particularly in patients with CRF.

Authors+Show Affiliations

Department of Laboratory Medicine, Iwate Medical University, 19-1 Uchimaru, 020-8505, Morioka, Japan. keikoyn@iwate-med.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15067515

Citation

Nakai, Keiko, et al. "Serum Levels of Cardiac Troponin I and Other Marker Proteins in Patients With Chronic Renal Failure." Clinical and Experimental Nephrology, vol. 8, no. 1, 2004, pp. 43-7.
Nakai K, Nakai K, Nagane Y, et al. Serum levels of cardiac troponin I and other marker proteins in patients with chronic renal failure. Clin Exp Nephrol. 2004;8(1):43-7.
Nakai, K., Nakai, K., Nagane, Y., Obara, W., Sato, M., Ohi, K., Matsumoto, N., Takanashi, N., & Itoh, C. (2004). Serum levels of cardiac troponin I and other marker proteins in patients with chronic renal failure. Clinical and Experimental Nephrology, 8(1), 43-7.
Nakai K, et al. Serum Levels of Cardiac Troponin I and Other Marker Proteins in Patients With Chronic Renal Failure. Clin Exp Nephrol. 2004;8(1):43-7. PubMed PMID: 15067515.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum levels of cardiac troponin I and other marker proteins in patients with chronic renal failure. AU - Nakai,Keiko, AU - Nakai,Kenji, AU - Nagane,Yutaka, AU - Obara,Wataru, AU - Sato,Michiro, AU - Ohi,Kiyofumi, AU - Matsumoto,Noriyuki, AU - Takanashi,Naoki, AU - Itoh,Chuichi, PY - 2003/03/10/received PY - 2003/11/10/accepted PY - 2004/4/7/pubmed PY - 2004/10/7/medline PY - 2004/4/7/entrez SP - 43 EP - 7 JF - Clinical and experimental nephrology JO - Clin Exp Nephrol VL - 8 IS - 1 N2 - BACKGROUND: Serum levels ob biochemical markers for acute myocardial infarction (AMI) can be increased in patients with chronic renal failure (CRF) or skeletal muscle injury, creating diagnostic confusion. We evaluated the clinical utility of cardiac troponin I (cTnI) as a marker of AMI, particularly in patients with CRF. METHODS: Subjects consisted of 59 healthy volunteers and 102 patients: 61 with CRF undergoing hemodialysis (CRF-HD), 10 with CRF under conservative therapy (CRF-CT), 21 with renal disease (RD), and 10 with muscle disease (MD). Patients with RD, CRF, and MD were evaluated to verify the absence of myocardial injury. We developed an immunoradiometric assay to measure serum cTnI using monoclonal antibodies. The lower limit of detection was 0.33 micro g/l. Serum cTnI, creatine kinase (CK), CK-MB, cardiac troponin T (first-, second-, and third-generation assay: cTnT-I, cTnT-II, and cTnT-III), and cardiac myosin light chain 1 (cMLC1) were measured. RESULTS: cTnI was not detected in healthy volunteers or patients with CRF, RD, or MD. In patients with CRF-HD, elevated levels occurred in 4.9% (3/61) for CK, 0% (0/61) for CK-MB, 39.5% (15/38) for cTnT-I, 7.3% (3/41) for cTnT-II, 13.0% (3/23) for cTnT-III, and 77.0% (47/61) for cMLC1; and in patients with MD the levels were increased in 70% (7/10) for CK, 50% (5/10) for CK-MB, 44.4% (4/9) for cTnT-I, 20% (2/10) for cTnT-II, and 50% (5/10) for cMLC1. CONCLUSIONS: cTnI is a highly specific marker for AMI and is particularly useful for detecting AMI in patients with CRF or MD. Serum levels of biochemical markers for acute myocardial infarction (AMI) can be increased in patients with chronic renal failure (CRF) or skeletal muscle injury, creating diagnostic confusion. We evaluated the clinical utility of cardiac troponin I (cTnI) as a marker of AMI, particularly in patients with CRF. SN - 1342-1751 UR - https://www.unboundmedicine.com/medline/citation/15067515/Serum_levels_of_cardiac_troponin_I_and_other_marker_proteins_in_patients_with_chronic_renal_failure_ L2 - https://dx.doi.org/10.1007/s10157-003-0266-7 DB - PRIME DP - Unbound Medicine ER -